Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study

Genes and Immunity

Volumn 16, Issue 5, 2015, Pages 321-329

  Noureddin, M ^a,b   Rotman, Y ^a   Zhang, F ^a   Park, H ^a   Rehermann, B ^a   Thomas, E ^a   Liang, T J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA1 INTERFERON; ASPARTATE AMINOTRANSFERASE; BETA1 INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 15; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; LAMBDA4 INTERFERON; MESSENGER RNA; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD; DRUG EFFECTS; GENETICS; HEPATITIS C, CHRONIC; LIVER; METABOLISM; PHENOTYPE;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERONS; LIVER; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN;

EID: 84937816422     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2015.11     Document Type: Article

References (39)

1. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009; 29(Suppl 1): 89-99.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
3. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907-1917.
4. Liang TJ, Ghany MG. Therapy of Hepatitis C-Back to the Future. N Engl J Med 2014; 370: 2043-2047.
5. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124: 3352-3363.
6. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR et al. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; 209: 1700-1704.
7. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978-988.
8. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA. 2008; 105: 7034-7039.
9. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-1444.
10. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
11. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
12. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
13. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
14. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology 2010; 138: 1338-1345 45 e1-7.
15. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171.
16. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116.
17. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15: 72-79.
18. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-1876.
19. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012; 56: 2060-2070.
20. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
21. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L et al. Interferoninduced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031.
22. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54: 1094-1101.
23. Abe H, Hayes CN, Ochi H, Tsuge M, Miki D, Hiraga N et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83: 1597-1607.
24. Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 2012; 55: 20-29.
25. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
26. Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013; 58: 1548-1557.
27. Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2014; 63: 161-169.
28. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
29. Meier V, Mihm S, Ramadori G. Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes. J Med Virol 2008; 80: 1912-1918.
30. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009; 29: 4841-4851.
31. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006; 43: 961-972.
32. Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, Uchida K et al. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat 2004; 11: 136-140.
33. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
34. Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I et al. IFNlambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J Exp Med 2014; 211: 857-868.
35. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563.
36. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006; 131: 1584-1591.
37. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PloS One 2013; 8: e84026.
38. Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014; 59: 1692-1705.
39. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26: 317-325.